|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
50,296,000 |
Market
Cap: |
207.22(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$1.9 - $40.3 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Ventyx Biosciences is a clinical-stage biopharmaceutical company engaged in the development of therapies for patients living with inflammatory diseases and autoimmune disorders. Co.'s product candidate is VTX958, an oral, selective clinical-stage tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis and Crohn's disease, among other potential indications. In addition, Co. is developing VTX002, an oral, selective sphingosine 1 phosphate receptor 1 modulator for ulcerative colitis. Co.'s oral, selective and peripherally restricted NLRP3 inhibitor, VTX2735, has been designed to treat systemic inflammatory diseases, such as cardiovascular, hepatic, renal and rheumatologic diseases.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
9,019 |
90,800 |
3,592,266 |
6,036,052 |
Total Sell Value |
$48,733 |
$221,937 |
$56,317,001 |
$133,915,096 |
Total People Sold |
4 |
4 |
7 |
8 |
Total Sell Transactions |
4 |
7 |
60 |
103 |
End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Auster Martin |
Chief Financial Officer |
|
2023-04-25 |
4 |
OE |
$3.45 |
$96,600 |
D/D |
28,000 |
75,649 |
|
- |
|
Subramaniam Somu |
Director |
|
2023-04-25 |
4 |
AS |
$38.88 |
$30,832 |
I/I |
(793) |
9,877,045 |
|
-10% |
|
Nsv Partners Iii Gp Llc |
10% Owner |
|
2023-04-25 |
4 |
AS |
$38.88 |
$30,832 |
I/I |
(793) |
9,877,045 |
|
-10% |
|
Subramaniam Somu |
Director |
|
2023-04-24 |
4 |
AS |
$37.95 |
$3,498,983 |
I/I |
(90,565) |
9,877,838 |
|
-14% |
|
Nsv Partners Iii Gp Llc |
10% Owner |
|
2023-04-24 |
4 |
AS |
$37.95 |
$3,498,983 |
I/I |
(90,565) |
9,877,838 |
|
-14% |
|
Subramaniam Somu |
Director |
|
2023-04-21 |
4 |
AS |
$37.51 |
$324,178 |
I/I |
(8,642) |
9,968,403 |
|
-11% |
|
Nsv Partners Iii Gp Llc |
10% Owner |
|
2023-04-21 |
4 |
AS |
$37.51 |
$324,178 |
I/I |
(8,642) |
9,968,403 |
|
-11% |
|
Auster Martin |
Chief Financial Officer |
|
2023-04-17 |
4 |
AS |
$33.00 |
$231,013 |
D/D |
(7,000) |
47,649 |
|
-7% |
|
Auster Martin |
Chief Financial Officer |
|
2023-04-17 |
4 |
OE |
$3.45 |
$24,150 |
D/D |
7,000 |
54,649 |
|
- |
|
Nsv Partners Iii Gp Llc |
10% Owner |
|
2023-04-13 |
4 |
AS |
$30.31 |
$2,165,800 |
I/I |
(71,446) |
9,977,045 |
|
4% |
|
Subramaniam Somu |
Director |
|
2023-04-13 |
4 |
AS |
$30.31 |
$2,165,800 |
I/I |
(71,446) |
9,977,045 |
|
4% |
|
Nsv Partners Iii Gp Llc |
10% Owner |
|
2023-04-12 |
4 |
AS |
$30.01 |
$856,866 |
I/I |
(28,554) |
10,048,491 |
|
5% |
|
Subramaniam Somu |
Director |
|
2023-04-12 |
4 |
AS |
$30.01 |
$856,866 |
I/I |
(28,554) |
10,048,491 |
|
5% |
|
Mohan Raju |
Chief Executive Officer |
|
2023-04-10 |
4 |
AS |
$29.01 |
$268,519 |
D/D |
(9,255) |
1,573,126 |
|
4% |
|
Subramaniam Somu |
Director |
|
2023-04-06 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,747,098) |
10,077,045 |
|
- |
|
Nsv Partners Iii Gp Llc |
10% Owner |
|
2023-04-06 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,747,098) |
10,077,045 |
|
- |
|
Mohan Raju |
Chief Executive Officer |
|
2023-04-06 |
4 |
AS |
$29.01 |
$217,991 |
D/D |
(7,515) |
1,582,381 |
|
5% |
|
Mohan Raju |
Chief Executive Officer |
|
2023-04-05 |
4 |
AS |
$29.61 |
$394,411 |
D/D |
(13,230) |
1,589,896 |
|
7% |
|
Auster Martin |
Chief Financial Officer |
|
2023-04-04 |
4 |
AS |
$30.24 |
$646,035 |
D/D |
(21,000) |
47,649 |
|
4% |
|
Auster Martin |
Chief Financial Officer |
|
2023-04-04 |
4 |
OE |
$3.45 |
$72,450 |
D/D |
21,000 |
68,649 |
|
- |
|
Krueger Christopher W |
Chief Business Officer |
|
2023-04-03 |
4/A |
AS |
$32.88 |
$493,166 |
D/D |
(15,000) |
276,117 |
|
- |
|
Krueger Christopher W |
Chief Business Officer |
|
2023-04-03 |
4/A |
OE |
$3.54 |
$32,040 |
D/D |
8,447 |
291,117 |
|
- |
|
Nuss John |
Chief Scientific Officer |
|
2023-04-03 |
4 |
AS |
$32.87 |
$986,233 |
D/D |
(30,000) |
244,815 |
|
2% |
|
Nuss John |
Chief Scientific Officer |
|
2023-04-03 |
4 |
OE |
$0.20 |
$6,000 |
D/D |
30,000 |
274,815 |
|
- |
|
Subramaniam Somu |
Director |
|
2023-03-17 |
4 |
D |
$0.00 |
$0 |
I/I |
(591,276) |
11,824,143 |
|
- |
|
178 Records found
|
|
Page 5 of 8 |
|
|